316 related articles for article (PubMed ID: 21128693)
1. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Gold R
CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
[TBL] [Abstract][Full Text] [Related]
2. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
3. Emerging oral drugs for multiple sclerosis.
Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
[TBL] [Abstract][Full Text] [Related]
4. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
5. [Oral treatments in multiple sclerosis].
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
[TBL] [Abstract][Full Text] [Related]
6. Recognizing and overcoming potential barriers to oral medications for MS.
Moses H
J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
[TBL] [Abstract][Full Text] [Related]
7. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Lu E; Wang BW; Alwan S; Synnes A; Dahlgren L; Sadovnick AD; Tremlett H
CNS Drugs; 2014 Feb; 28(2):89-94. PubMed ID: 24343726
[TBL] [Abstract][Full Text] [Related]
8. Drugs: An injection of hope.
Graham-Rowe D
Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
[No Abstract] [Full Text] [Related]
9. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
10. The future of multiple sclerosis therapy.
Kieseier BC; Wiendl H; Hartung HP; Stüve O
Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009
[TBL] [Abstract][Full Text] [Related]
11. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in relapsing-remitting multiple sclerosis.
Marriott JJ; O'Connor PW
Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
[TBL] [Abstract][Full Text] [Related]
13. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Kretzschmar B; Pellkofer H; Weber MS
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
17. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
18. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
di Nuzzo L; Orlando R; Nasca C; Nicoletti F
Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
[TBL] [Abstract][Full Text] [Related]
19. Novel oral agents for multiple sclerosis.
Burton JM; O'Connor P
Curr Neurol Neurosci Rep; 2007 May; 7(3):223-30. PubMed ID: 17488588
[TBL] [Abstract][Full Text] [Related]
20. Oral Therapies for Multiple Sclerosis.
Faissner S; Gold R
Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]